References
- BACH, M. V., COUTTS, R. T. and BAKER, G. B., 2000, Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line. Xenobiotica, 30, 297–306.
- BECKETT, A. H. and ROWLAND, M., 1965, Urinary excretion kinetics of methyl-amphetamine in man. Journal of Pharmacy and Pharmacology, 17, 109S–114S.
- CROSSLEY, F. S. and MOORE, M. L., 1944, Studies on the Leuckart reaction. Journal of Organic Chemistry, 9, 529–536.
- GRACE, J. M., KINTER, M. T. and MACDONALD, T. L., 1994, Typical metabolism of deprenyl and its enantiomer, (S)-(+)-N, ce-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chemical Research in Toxicology, 7, 286–290.
- HEINONEN, E. H. and LAMMINTAUSTA, R., 1991, A review of the pharmacology of selegiline. Ada Neurologica Scandinavica, 84(suppl.), 44–59.
- HEINONEN, E. H., ANTTILA, M. I. and LAMMINTAUSTA, R. A., 1994, Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clinical Pharmacology and Therapeutics, 56, 742–749.
- HIDESTRAND, M., OSCARSON, M., SALONEN, J. S., NYMAN, L., PELKONEN, O., TURPEINEN, M. and INGELMANSUNDBERG, M., 2001, CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metabolism and Disposition, 29, 1480–1484.
- JENNER, P., 1971, The role of nitrogen oxidation in the excretion of drugs and foreign compounds. Xenobiotica, 1, 399–418.
- KATAGI, M., TATSUNO, M., MIKI, A., NISHIKAWA, M., NAKAJIMA, K. and TSUCHIHASHI, H., 2001, Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography B, 759, 125–133.
- KNOLL, J., 1978, The possible mechanisms of action of (—)deprenyl in Parkinson's disease. Journal of Neural Transmission, 43, 177–198.
- LEMOINE, A., JOHANN, M. and CRESTEIL, T., 1990, Evidence for the presence of distinct flavin- containing monooxygenases in human tissues. Archives of Biochemistry and Biophysics, 276, 336–342.
- LENGYEL, J., MAGYAR, K., HoLLOI, I., BARTOK, T., BATHORI, M., KALASZ, H. and FuRsT, S., 1997, Urinary excretion of deprenyl metabolites. Journal of Chromatography A, 762, 321–326.
- MAURER, H. H. and KRAEMER, T., 1992, Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectro-metry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Archives of Toxicology, 66, 675–678.
- POULSEN, L. L. and ZIEGLER, D. M., 1979, The liver microsomal FAD-containing monooxygenase. Spectral characterization and kinetic studies. Journal of Biological Chemistry, 254, 6449–6455.
- SHIN, H. S., 1997, Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metabolism and Disposition, 25, 657–662.
- SZATMARI, I. and Tom, K., 1992, Pharmacokinetics and metabolism of selegiline. Acta Pharmaceutica Hungarica, 62, 243–248.
- TAAVITSAINEN, P., ANTTILA, M., NYMAN, L., KARNANI, H., SALONEN, J. S. and PELKONEN, O., 2000, Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacology and Toxicology, 86, 215–221.
- YAMAZAKI, M., ISLAM, M. N., TAKIKITA, S., OGURA, Y., TERADA, M., NAKATOME, M., KUROKI, H. and HONDA, K., 1999, Immunohistochemical and enzymological studies of flavin (FAD)-containing monooxygenase in human liver. Japanese Journal of Forensic Toxicology, 17, 30–41.
- ZIEGLER, D. M., 1988, Flavin-containing monooxygenase: catalytic mechanism and substrate specificities. Drug Metabolism Reviews, 19, 1–32.